Parabilis Medicines Updates Executive Leadership Team

Parabilis Medicines, a clinical-stage biotechnology company focused on developing peptide-based cancer therapies, has appointed Helen Ho as Chief Business and Strategy Officer and promoted Thomas Kotarakos to Chief Financial Officer.

Dr. Helen Ho, Chief Business and Strategy Officer

Ho joins Parabilis with more than 20 years of experience in biopharmaceutical strategy and corporate development. She most recently served as chief business officer at Blueprint Medicines, where she helped lead corporate strategy and executed more than a dozen transactions that generated over $1 billion in proceeds. Earlier in her career, she held corporate development roles at TCR2 Therapeutics and Agios Pharmaceuticals.

In her new role, Ho will oversee Parabilis’s growth strategy, business development, and portfolio management, as well as corporate communications, alliance management, and competitive intelligence. She holds a Ph.D. in cell biology from Yale University and a bachelor’s degree in biochemistry from the University of California, Los Angeles.

Thomas Kotarakos, Chief Financial Officer

Kotarakos was promoted after holding senior finance roles at Parabilis since joining the company in 2021. He has overseen several private financings, including the company’s $305 million Series F round completed in January. As chief financial officer, he will continue to lead financial strategy, investor relations, and operational functions, including IT and facilities.

Before joining Parabilis, Kotarakos served as senior vice president of finance and business operations at Codiak BioSciences and previously held senior finance positions at Seres Therapeutics. He is a certified public accountant and holds undergraduate and master’s degrees in accounting from Bentley University.